Stifel Financial Corp Sells 24,859 Shares of DexCom, Inc. (NASDAQ:DXCM)

Stifel Financial Corp lessened its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,871 shares of the medical device company's stock after selling 24,859 shares during the period. Stifel Financial Corp's holdings in DexCom were worth $6,226,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in DXCM. ORG Partners LLC grew its stake in shares of DexCom by 1,992.0% in the 2nd quarter. ORG Partners LLC now owns 523 shares of the medical device company's stock worth $59,000 after acquiring an additional 498 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its position in DexCom by 2.0% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 27,268 shares of the medical device company's stock worth $3,092,000 after purchasing an additional 547 shares in the last quarter. Swedbank AB increased its stake in DexCom by 5.0% in the 2nd quarter. Swedbank AB now owns 185,575 shares of the medical device company's stock valued at $21,040,000 after buying an additional 8,795 shares during the last quarter. Blue Trust Inc. lifted its position in shares of DexCom by 128.8% during the 2nd quarter. Blue Trust Inc. now owns 881 shares of the medical device company's stock worth $100,000 after buying an additional 496 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. boosted its stake in shares of DexCom by 14.4% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company's stock worth $183,336,000 after buying an additional 203,043 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on DXCM shares. Citigroup lifted their price target on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday. Stifel Nicolaus lifted their target price on DexCom from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, August 23rd. JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Royal Bank of Canada lowered their price objective on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $98.00.

DexCom Price Performance

DXCM stock traded down $1.74 during mid-day trading on Friday, reaching $77.19. 2,956,879 shares of the company traded hands, compared to its average volume of 3,884,590. The company has a fifty day moving average price of $73.76 and a 200-day moving average price of $84.65. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a market capitalization of $30.15 billion, a P/E ratio of 46.22, a P/E/G ratio of 2.46 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.